PepCan

BIOLOGICAL2 trials

Sponsors

University of Arkansas

Conditions

Cervical Intraepithelial NeoplasiaHead and Neck Cancer

Phase 1

A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients

CompletedNCT03821272

University of ArkansasHead and Neck Cancer

Start: 2019-11-13End: 2025-02-03Updated: 2025-10-08

Phase 2

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

CompletedNCT02481414

University of ArkansasCervical Intraepithelial Neoplasia

Start: 2015-11-30End: 2022-09-14Updated: 2023-12-18

Related Papers

Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.

Journal of Clinical Oncology2024-06-011 citations

A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).

Journal of Clinical Oncology2023-06-012 citations